Hugo Mouquet researcher
Mouquet, Hugo, 1977-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 193981686 (Personal)
Permalink: http://viaf.org/viaf/193981686
Preferred Forms
-
100 0 _
‡a
Hugo Mouquet
‡c
researcher
-
100 1 _
‡a
Mouquet, Hugo,
‡d
1977-....
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges |
|
| Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient |
|
| Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity |
|
| Antibodies in HIV-1 vaccine development and therapy |
|
| Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia |
|
| Characterisation of autoreactives B cells in Sjögren's syndrome. |
|
| A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations |
|
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies |
|
| Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. |
|
| COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study |
|
| [CRISPR-Cas9 editing of HIV-1 neutralizing human B cells] |
|
| Design and caracterisation of non immunogenic antibodies : application to an anti-Salmonella/Shigella antibody. |
|
| Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells |
|
| Diversity of Human Immunodeficiency Virus 1 and evolution of its sensitivity to neutralizing antibodies : analyses at the individual and the populationnal levels. |
|
| Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice |
|
| Drift of the envelope glycoprotein of HIV-1 over the course of the epidemic : enhanced resistance to neutralizing antibodies and improved functionality. |
|
| Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV infected patients. |
|
| Efficient generation of human IgA monoclonal antibodies |
|
| ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. |
|
| Enhanced HIV-1 neutralization by antibody heteroligation |
|
| Etude de la réponse immunitaire induite par le ciblage des cellules de Langerhans par des anticorps monoclonaux fusionnés avec des antigènes du VIH-1. |
|
| Évaluation du rôle de l'interleukine 1 dans la régulation des lymphocytes T folliculaires helpers et des lymphocytes T folliculaires régulateurs |
|
| Feedback control of regulatory T cell homeostasis by dendritic cells in vivo |
|
| Genetic factors in pemphigus |
|
| Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir. |
|
| HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells |
|
| HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice |
|
| HIV: Roadmaps to a vaccine |
|
| HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection |
|
| Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness |
|
| Humanized mouse models to study pathophysiology and treatment of HIV infection |
|
| Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies? |
|
| Identification, caractérisation moléculaire et étude des propriétés fonctionnelles des anticorps neutralisants à large spectre contre le VIH-1 |
|
| Identification, molecular characterization and functional properties of broadly neutralizing antibodies against HIV-1. |
|
| Immunogenetics of pemphigus: an update |
|
| Impact of Antigen Density on the Binding Mechanism of IgG Antibodies |
|
| Implication du couple CD83 membranaire / CD83 soluble dans le pemphigus auto-immun |
|
| Involvement of membrane CD83 |
|
| Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies |
|
| L'initiation précoce du traitement antirétroviral conserve la fonction immunitaire dans l'intestin de patients infectés par le VIH |
|
| Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses |
|
| A method for identification of HIV gp140 binding memory B cells in human blood |
|
| Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas |
|
| Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques |
|
| Polyreactive antibodies in adaptive immune responses to viruses |
|
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation |
|
| Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals |
|
| Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity |
|
| The role of autoantigens in autoimmune diseases : study of desmoglein 1 in the course of pemphigus. |
|
| Role of interleukin1 on Tfh cell regulation by Tfr cells. |
|
| Rupture of immune tolerance during HCV-associated cryoglobulinemia vasculitis. |
|
| SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors. |
|
| Scarcity of autoreactive human blood IgA+ memory B cells |
|
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding |
|
| A single cycle of rituximab for the treatment of severe pemphigus. |
|
| Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization |
|
| Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody |
|
| Study of the immune response induced by the targeting of Langerhans cells with monoclonal antibodies fused with HIV-1 antigens |
|
| Tailored immunogens for rationally designed antibody-based HIV-1 vaccines |
|
| TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice |
|
| V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1 |
|
| The value of open-source clinical science in pandemic response: lessons from ISARIC |
|
| What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1. |
|
